GlassScriptPhysician profile
Shawna Karman
NPI 1689070963
$3,985.69
in general payments reported to CMS, 2019-2025
29 companies · $484 in 2025
The $484 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $630 · 2022: $874 · 2023: $1,142 · 2024: $855 · 2025: $484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,423 · Education: $58.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,422.75 |
| Education | $58.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $851.06 | 2021-2024 | |
| Novo Nordisk INC | $568.52 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $443.44 | 2021-2024 | Mounjaro, Trulicity, Emgality |
| Astrazeneca Pharmaceuticals LP | $286.23 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $188.21 | 2022-2024 | |
| Inspire Medical Systems, INC. | $167.00 | 2023-2025 | Inspire |
| Merck Sharp & Dohme LLC | $142.41 | 2021-2023 | Vaxneuvance, Gardasil 9, M-M-R II |
| Abbott Laboratories | $129.12 | 2022-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Pfizer INC. | $126.80 | 2021-2024 | |
| Glaxosmithkline, LLC. | $125.32 | 2023-2025 | Trelegy Ellipta, Nucala, Shingrix |
| Optinose US, INC. | $122.38 | 2025 | |
| Astellas Pharma US INC | $111.70 | 2021-2024 | Veozah |
| Daiichi Sankyo INC. | $93.86 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $78.90 | 2025 | Dupixent |
| Smith+Nephew, INC. | $58.54 | 2025 | Tula |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $53.12 | 2023-2024 | Rexulti |
| Hologic Sales and Service, LLC | $50.89 | 2021-2024 | Thinprep 2000 Processor |
| Janssen Pharmaceuticals, INC | $49.69 | 2023-2024 | Xarelto |
| Corium, LLC | $44.75 | 2023-2024 | Azstarys |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.53 | 2022 | |
| Currax Pharmaceuticals LLC | $43.71 | 2022-2023 | Contrave |
| Dexcom, INC. | $43.48 | 2023-2024 | Dexcom G6 Transmitter |
| Lucid Diagnostics INC. | $29.39 | 2022-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.01 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.49 | 2021-2024 | Trulance, Xifaxan |
| Biohaven Pharmaceuticals, INC. | $27.42 | 2021 | |
| Xeris Pharmaceuticals, INC. | $18.73 | 2024 | Gvoke Hypopen |
| Vbi Vaccine (Delaware) INC. | $16.38 | 2022 | |
| Coopersurgical, INC. | $12.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawna Karman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.